High frequency of melanoma-associated antigen or hla class i loss does not correlate with survival in primary melanoma

Journal of Immunotherapy

Volumn 27, Issue 1, 2004, Pages 73-78

  Hofbauer, Günther F L ^a   Burkhart, Andrea ^a   Schüler, Georges ^a   Dummer, Reinhard ^a   Burg, Günter ^a   Nestle, Frank O ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

HLA class I; Immunotherapy; MAGE 3; MelanA MART 1; Melanoma associated antigens

Indexed keywords

GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EVALUATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MELANOMA; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, NEOPLASM; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; SURVIVAL RATE; TIME FACTORS;

EID: 0347915730     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200401000-00007     Document Type: Article

References (40)

1. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999; 10:281.
2. Boon T, Vanderbruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996; 183:725.
3. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today. 1999; 20:5.
4. Castelli C, Rivoltini L, Andreola G, et al. T-cell recognition of melanoma-associated antigens. J Cell Physiol. 2000; 182:323.
5. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4:328.
6. Curiel-Lewandrowski C, Demierre M. Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol. 2000; 43:167.
7. Jäger D, Jäger E, Knuth A. Vaccination for malignant melanoma: recent developments. Oncology. 2001; 60:1.
8. Geertsen RC, Hofbauer GF, Yue FY, et al. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J Invest Dermatol. 1998; 111:497.
9. Hofbauer GFL, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol. 1997; 151:1549.
10. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998; 8:337.
11. Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998; 25:204.
12. Stadelmann WK, Rapaport DP, Soon SJ, et al. Prognostic clinical and pathologic features. In: Balch VM, Houghton AN, Sober AJ, et al., eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998:11.
13. Reed JA, Albino AP. Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Clin Lab Med. 2000; 20:817.
14. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995; 75:2492.
15. Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Clin Lab Med. 2000; 20:785.
16. Keilholz U. New prognostic factors in melanoma: mRNA tumour markers. Eur J Cancer. 1998; 34(suppl 3):S37.
17. Kashani-Sabet M, Leong SP, Sagebiel R. Prognostic factors in malignant melanoma. Surg Oncol Clin North Am. 1997; 6:599.
18. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995; 181:193.
19. Jäger E, Jäger D, Knuth A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 1999; 18:143.
20. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med. 2001; 7:761.
21. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci. 1998; 3:1005.
22. Mocellin S, Ohnmacht GA, Nielsen MB, et al. Short-term kinetics of tumor antigen expression in response to vaccination. Int J Cancer. 2001; 93:841.
23. Jungbluth AA, Busam KJ, Kolb D, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 2000; 85:460.
24. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg. 1975; 182:572.
25. Busam KJ, Iversen K, Berwick M, et al. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol. 2000; 13:459.
26. Gotoh K, Yatabe Y, Sugiura T, et al. Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer. 1998; 20:117.
27. Corrias MV, Scaruffi P, Occhino M, et al. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer. 1996; 69:403.
28. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother. 1996; 19:192.
29. Mehregan DR, Hamzavi I. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells. Am J Dermatopathol. 2000; 22:247.
30. Kageshita T, Kawakami Y, Hirai S, et al. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 1997; 20:460.
31. de Vries TJ, Fourkour A, Wobbes T, et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997; 57:3223.
32. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998; 22:595.
33. Berset M, Cerottini JP, Guggisberg D, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer. 2001; 95:73.
34. Niezabitowski A, Czajecki K, Rys J, et al. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol. 1999; 70:150.
35. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995; 16:487.
36. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. 1994; 153:1225.
37. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res. 1993; 53:3349.
38. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999; 154:745.
39. Gillespie AM, Coleman RE. The potential of melanoma antigen expression in cancer therapy. Cancer Treat Rev. 1999; 25:219.
40. Wolfe JT. The role of screening in the management of skin cancer. Curr Opin Oncol. 1999; 11:123.